Derma Sciences to Showcase MEDIHONEY® and TCC-EZ® at Novation Innovative Technology Expo
Annual event highlights new technology that increases safety and
improves patient outcomes
PRINCETON, N.J.--(BUSINESS WIRE)--
Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and
pharmaceutical company focused on advanced wound care, is showcasing its
MEDIHONEY® line of advanced wound care dressings and its TCC-EZ® Total
Contact Casting system at the Novation Innovative Technology Expo today
at the Irving Convention Center in Las Colinas, TX. The event provides
medical technology suppliers the opportunity to gain direct feedback
from onsite clinical experts and healthcare providers on the impact
their products have on improving patient care and reducing the risk of
harm to patients and caregivers.
MEDIHONEY is the global leading line of medical-grade honey products for
the management of wounds and burns. Derived from the Leptospermum
scoparium species of plant in New Zealand, these unique dressings
have properties that are beneficial throughout all phases of wound
healing. MEDIHONEY offers a full line of dressing solutions, providing
versatility for varying wound conditions and wound management needs.
MEDIHONEY was recognized by Novation as a finalist for the 2011
Innovative Technology Award and was selected as a finalist by Novation
members, based on the product's impact on patient care and improving
Total Contact Casting is recognized as the Gold Standard of care for
diabetic foot ulcers. TCC-EZ offers a one-piece, roll-on, woven design
that simplifies the casting while reducing the potential for causing
additional tissue damage. The application process can be completed in
less than 10 minutes while providing greater patient comfort.
"We are delighted once again to be participating in Novation's
Innovative Technology Expo, and are pleased that Novation has provided
us with the opportunity to showcase the attributes of our two advanced
wound care anchor product lines," said Barry Wolfenson, Group President,
Advanced Wound Care and Pharmaceutical Development of Derma Sciences.
"We have a long and productive relationship with Novation and are very
pleased that MEDIHONEY is under an Innovative Technology agreement. We
are also pleased to have submitted TCC-EZ as a novel technology in
helping to advance patient care for diabetic foot ulcers, and are
hopeful to receive our second Innovative Technology Award."
Participating companies include those who have submitted products for
evaluation or have already been awarded a contract by Novation, the
leading healthcare supply chain expertise, analytics and contracting
company for the 65,000 members and affiliates of VHA Inc., UHC,
Children's Hospital Association and Provista LLC.
Since 2003, more than 1,500 new and innovative technologies have been
submitted through the Novation Innovative Technology program. Novation
works with member-led councils and task forces to identify and review
potentially innovative technology. Once these teams have evaluated the
technology and determined that it provides an incremental clinical
benefit over existing products, a contract for the innovative technology
may be awarded outside of Novation's competitive bid cycle.
To learn more about Novation's Innovative Technology program, visit www.novationco.com/expertise/technology.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments
of the wound care marketplace: pharmaceutical wound care products;
advanced wound care dressings to address chronic wounds including
diabetic ulcers; and traditional dressings. The Company has begun Phase
3 clinical trials in diabetic foot ulcer healing with DSC127, based on
excellent Phase 2 data. Its MEDIHONEY® product is the leading brand of
honey-based dressings for the management of wounds and burns. The
product has been shown in clinical studies to be effective in a variety
of indications. TCC-EZ® is its gold-standard total contact casting
system for diabetic foot ulcers. Other novel products introduced into
the $14 billion global wound care market include XTRASORB® for better
management of wound exudate, and BIOGUARD® for infection prevention.
For more information please visit www.dermasciences.com.
About Novation, Winner of the Ethics Inside® Certification
Founded in 1998, Novation is the leading health care supply chain
expertise, analytics and contracting company for the more than 65,000
members and affiliates of VHA Inc. and UHC, two national health care
alliances, Children's Hospital Association, an alliance of the nation's
leading pediatric facilities, and Provista, LLC. Novation provides
alliance members with sourcing services, as well as information and data
services. Based in Irving, Texas, Novation develops and manages
competitive contracts with more than 600 suppliers. VHA, UHC, and
Provista members used Novation contracts to purchase approximately $43
billion in 2012. Novation has earned the coveted Ethics Inside®
Certification from Ethisphere Institute, a leading international think
tank dedicated to the research and promotion of best practices in
corporate ethics and compliance. Novation also was named on Ethisphere's
World's Most Ethical Companies list, and is the only company in the
health care industry to earn both distinctions for two consecutive
years. To learn more about Novation, please visit www.novationco.com
and follow @NovationNews.
Statements contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the generality of the foregoing, words such as "may," "will,"
"expect," "believe," "anticipate," "intend," "could," "estimate" or
"continue" are intended to identify forward-looking statements. Readers
are cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially from
any forward-looking statements that may be made in this news release or
that are otherwise made by or on behalf of the Company. Factors that may
affect the Company's results include, but are not limited to, product
demand, market acceptance, impact of competitive products and prices,
product development, completion of an acquisition, commercialization or
technological difficulties, the success or failure of negotiations and
trade, legal, social and economic risks. Additional factors that could
cause or contribute to differences between the Company's actual results
and forward-looking statements include but are not limited to, those
discussed in the Company's filings with the U.S. Securities and Exchange
Source: Derma Sciences, Inc.